0000000000524578

AUTHOR

Alexander Kreuter

0000-0003-2275-499x

showing 6 related works from this author

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCL…

2012

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensi…

AdultMalemedicine.medical_specialtyPathologyDatabases FactualAnti-nuclear antibodyCross-sectional studyImmunologyDiseaseDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineSurveys and QuestionnairesInternal medicineLupus Erythematosus CutaneousmedicineHumansImmunology and AllergyProspective StudiesAge of OnsetGeography MedicalProspective cohort studyAgedSkin030203 arthritis & rheumatologyAutoimmune diseaseLupus erythematosusbusiness.industryfungiAge FactorsMiddle Agedmedicine.diseaseDermatologyRheumatology3. Good healthEuropeCross-Sectional StudiesFemaleAge of onsetbusinessAutoimmunity Reviews
researchProduct

Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.

2009

Background Nephrogenic systemic fibrosis (NSF) affects some patients on dialysis after gadolinium contrast agent–enhanced magnetic resonance imaging. It is characterized by progressive skin fibrosis of the extremities, sometimes including the trunk and internal organs. Methods The clinical course of 10 patients with biopsy-proven NSF was analyzed retrospectively with regard to gadolinium exposition, disease onset, and progression of NSF with special emphasis on physical mobility and impact of different therapeutic approaches. Results Despite physiotherapy and different additional therapeutic approaches (eg, immunosuppression, ultraviolet A-1 phototherapy, or extracorporal photopheresis) all…

Nephrogenic Fibrosing DermopathyAdultmedicine.medical_specialtymedicine.medical_treatmentBiopsyGadoliniumDermatologyHydronephrosisNephrectomyEnd stage renal diseaseNephrogenic Fibrosing DermopathyPhotopheresisFibrosisRenal DialysismedicineHumansKidney transplantationDialysisbusiness.industrymedicine.diseaseMagnetic Resonance ImagingSurgeryNephrogenic systemic fibrosisDisease ProgressionFemalebusinessKidney diseaseJournal of the American Academy of Dermatology
researchProduct

Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg study

2021

The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-res…

0301 basic medicineOncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizin610ArticleTargeted therapycomplete response03 medical and health sciences0302 clinical medicinedisease progressionInternal medicineMedicineddc:610second-line immunotherapyneoplasmsComplete responseRC254-282business.industryMelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyDiscontinuation030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisToxicityCohortSkin cancerbusinessdiscontinuation
researchProduct

Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas

2019

BACKGROUND Pleomorphic dermal sarcomas (PDS) are frequent UV-induced sarcomas of the skin of intermediate grade malignant potential. Despite the fact that PDS have a noteworthy potential to recur (up to 28%) as well as to metastasize (up to 20%), there are no specific clinical guidelines with respect to follow-up these patients. Moreover, little is known about clinical, histological or molecular prognostic factors in PDS. OBJECTIVE The aim of the present study was to identify risk factors to predict relapse in a large multicentre sample cohort of PDS which could aid to optimize personalized treatment recommendations regarding surgical safety margins and adjuvant radiotherapy. METHODS Patien…

AdultMale0301 basic medicineOncologymedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentDermatology03 medical and health sciences0302 clinical medicineInternal medicineStatistical significanceSurgical safetyHumansMedicineIntermediate GradeUlcerAgedAged 80 and overbusiness.industryProportional hazards modelHazard ratioMargins of Excisionfood and beveragesSarcomaImmunosuppressionMiddle AgedPrognosisConfidence interval030104 developmental biologyInfectious Diseases030220 oncology & carcinogenesisCohortFemalebusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis.

2013

Systemic sclerosis (SSc) is a fibrotic autoimmune disease in which the genetic component plays an important role. One of the strongest SSc association signals outside the human leukocyte antigen (HLA) region corresponds to interferon (IFN) regulatory factor 5 (IRF5), a major regulator of the type I IFN pathway. In this study we aimed to evaluate whether three different haplotypic blocks within this locus, which have been shown to alter the protein function influencing systemic lupus erythematosus (SLE) susceptibility, are involved in SSc susceptibility and clinical phenotypes. For that purpose, we genotyped one representative single-nucleotide polymorphism (SNP) of each block (rs10488631, r…

MaleLinkage disequilibrium:Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings]Polimorfismo de nucleótido simpleSLElcsh:MedicineAutoimmunityGenome-wide association studyLinkage DisequilibriumScleroderma:Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Gene Frequency:Named Groups::Persons::Population Groups::Continental Population Groups::European Continental Ancestry Group [Medical Subject Headings]Risk FactorsIRF5Genetics of the Immune SystemLupus Erythematosus Systemic:Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Scleroderma Systemic [Medical Subject Headings]skin and connective tissue diseaseslcsh:ScienceMultidisciplinary:Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus Systemic [Medical Subject Headings]Predisposición genética a la enfermedad:Phenomena and Processes::Genetic Phenomena::Genetic Linkage::Linkage Disequilibrium [Medical Subject Headings]:Phenomena and Processes::Genetic Phenomena::Genotype::Genetic Predisposition to Disease [Medical Subject Headings]PhenotypeInterferon Regulatory FactorsSYSTEMIC SCLEROSISMedicineEvaluation of complex medical interventions Auto-immunity transplantation and immunotherapy [NCEBP 2]FemaleIRF5; SLE; TYPE I INTERFERON; SYSTEMIC SCLEROSISHaplotiposResearch ArticleFactores de riesgoImmunology:Chemicals and Drugs::Amino Acids Peptides and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Adaptor Proteins Signal Transducing::Interferon Regulatory Factors [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]:Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings]Single-nucleotide polymorphismHuman leukocyte antigenBiologyPolymorphism Single NucleotideWhite PeopleAutoimmune DiseasesRheumatologyLupus eritematoso sistémicoGeneticsHumansGenetic Predisposition to DiseaseGrupo de ascendencia continental europeaAlleleBiologyAllele frequencyAllelesGenetic Association Studies:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings]Scleroderma SystemicHaplotypelcsh:R:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genetic Loci [Medical Subject Headings]Human Genetics:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism Genetic [Medical Subject Headings]Factores reguladores del interferónHaplotypesDesequilibrio de ligamiento:Check Tags::Female [Medical Subject Headings]Genetic LociTYPE I INTERFERONGenetics of DiseaseImmunologyGenetic PolymorphismClinical Immunologylcsh:Q:Phenomena and Processes::Genetic Phenomena::Gene Frequency [Medical Subject Headings]Population GeneticsIRF5PLoS ONE
researchProduct